A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics

Background and Aims. Chemotherapy of colorectal liver metastases can induce hepatotoxicity in noncancerous liver. We describe these lesions and assess risk factors and impacts on postresection morbidity and mortality in naive patients to chemotherapy before the era of bevacizumab. Methods. Noncancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Eric Nguyen-Khac, Céline Lobry, Denis Chatelain, David Fuks, Jean Paul Joly, Marie Brevet, Blaise Tramier, Charlotte Mouly, Vincent Hautefeuille, Bruno Chauffert, Jean Marc Regimbeau
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:International Journal of Hepatology
Online Access:http://dx.doi.org/10.1155/2013/314868
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850167231036522496
author Eric Nguyen-Khac
Céline Lobry
Denis Chatelain
David Fuks
Jean Paul Joly
Marie Brevet
Blaise Tramier
Charlotte Mouly
Vincent Hautefeuille
Bruno Chauffert
Jean Marc Regimbeau
author_facet Eric Nguyen-Khac
Céline Lobry
Denis Chatelain
David Fuks
Jean Paul Joly
Marie Brevet
Blaise Tramier
Charlotte Mouly
Vincent Hautefeuille
Bruno Chauffert
Jean Marc Regimbeau
author_sort Eric Nguyen-Khac
collection DOAJ
description Background and Aims. Chemotherapy of colorectal liver metastases can induce hepatotoxicity in noncancerous liver. We describe these lesions and assess risk factors and impacts on postresection morbidity and mortality in naive patients to chemotherapy before the era of bevacizumab. Methods. Noncancerous liver tissue lesions were analysed according to tumour, chemotherapy, surgery, and patient characteristics. Results. Fifty patients aged 62 ± 9.3 years were included between 2003 and 2007. Thirty-three (66%) received chemotherapy, with Folfox (58%), Folfiri (21%), LV5FU2 (12%), or Xelox (9%) regimens. Hepatotoxicity consisted of 18 (36%) cases of severe sinusoidal dilatation (SD), 13 (26%) portal fibrosis, 7 (14%) perisinusoidal fibrosis (PSF), 6 (12%) nodular regenerative hyperplasia (NRH), 2 (4%) steatosis >30%, zero steatohepatitis, and 16 (32%) surgical hepatitis. PSF was more frequent after chemotherapy (21% versus 0%, ), especially LV5FU2 (). SD was associated with oxaliplatin (54.5% versus 23.5%, ) and low body mass index (). NRH was associated with oxaliplatin () and extensive resection (). No impact on mortality and morbidity was observed, apart postoperative elevation of bilirubin levels in case of PSF (), longer hospitalization in case of surgical hepatitis (), and greater blood loss in case of portal fibrosis (). Conclusions. Chemotherapy of colorectal liver metastases induces sinusoidal dilatation related to oxaliplatin and perisinusoidal fibrosis related to 5FU, without any impact on postoperative mortality.
format Article
id doaj-art-e2b0ba0a7d9d4a1bb0be874e39fea5ef
institution OA Journals
issn 2090-3448
2090-3456
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series International Journal of Hepatology
spelling doaj-art-e2b0ba0a7d9d4a1bb0be874e39fea5ef2025-08-20T02:21:14ZengWileyInternational Journal of Hepatology2090-34482090-34562013-01-01201310.1155/2013/314868314868A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of AntiangiogenicsEric Nguyen-Khac0Céline Lobry1Denis Chatelain2David Fuks3Jean Paul Joly4Marie Brevet5Blaise Tramier6Charlotte Mouly7Vincent Hautefeuille8Bruno Chauffert9Jean Marc Regimbeau10Department of Hepatology, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Hepatology, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Pathology, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Digestive Surgery, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Hepatology, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Pathology, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceBiostatistic Department, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Digestive Surgery, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Hepatology, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Medical Oncology, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceDepartment of Digestive Surgery, Amiens University Hospital, Place Victor Pauchet, 80054 Amiens Cedex 01, FranceBackground and Aims. Chemotherapy of colorectal liver metastases can induce hepatotoxicity in noncancerous liver. We describe these lesions and assess risk factors and impacts on postresection morbidity and mortality in naive patients to chemotherapy before the era of bevacizumab. Methods. Noncancerous liver tissue lesions were analysed according to tumour, chemotherapy, surgery, and patient characteristics. Results. Fifty patients aged 62 ± 9.3 years were included between 2003 and 2007. Thirty-three (66%) received chemotherapy, with Folfox (58%), Folfiri (21%), LV5FU2 (12%), or Xelox (9%) regimens. Hepatotoxicity consisted of 18 (36%) cases of severe sinusoidal dilatation (SD), 13 (26%) portal fibrosis, 7 (14%) perisinusoidal fibrosis (PSF), 6 (12%) nodular regenerative hyperplasia (NRH), 2 (4%) steatosis >30%, zero steatohepatitis, and 16 (32%) surgical hepatitis. PSF was more frequent after chemotherapy (21% versus 0%, ), especially LV5FU2 (). SD was associated with oxaliplatin (54.5% versus 23.5%, ) and low body mass index (). NRH was associated with oxaliplatin () and extensive resection (). No impact on mortality and morbidity was observed, apart postoperative elevation of bilirubin levels in case of PSF (), longer hospitalization in case of surgical hepatitis (), and greater blood loss in case of portal fibrosis (). Conclusions. Chemotherapy of colorectal liver metastases induces sinusoidal dilatation related to oxaliplatin and perisinusoidal fibrosis related to 5FU, without any impact on postoperative mortality.http://dx.doi.org/10.1155/2013/314868
spellingShingle Eric Nguyen-Khac
Céline Lobry
Denis Chatelain
David Fuks
Jean Paul Joly
Marie Brevet
Blaise Tramier
Charlotte Mouly
Vincent Hautefeuille
Bruno Chauffert
Jean Marc Regimbeau
A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
International Journal of Hepatology
title A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
title_full A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
title_fullStr A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
title_full_unstemmed A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
title_short A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics
title_sort reappraisal of chemotherapy induced liver injury in colorectal liver metastases before the era of antiangiogenics
url http://dx.doi.org/10.1155/2013/314868
work_keys_str_mv AT ericnguyenkhac areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT celinelobry areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT denischatelain areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT davidfuks areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT jeanpauljoly areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT mariebrevet areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT blaisetramier areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT charlottemouly areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT vincenthautefeuille areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT brunochauffert areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT jeanmarcregimbeau areappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT ericnguyenkhac reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT celinelobry reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT denischatelain reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT davidfuks reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT jeanpauljoly reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT mariebrevet reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT blaisetramier reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT charlottemouly reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT vincenthautefeuille reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT brunochauffert reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics
AT jeanmarcregimbeau reappraisalofchemotherapyinducedliverinjuryincolorectallivermetastasesbeforetheeraofantiangiogenics